COVID-CP Banking
- Conditions
- D000086382coronavirus disease 2019COVID19 Plasma therapy Biobank Biobanking
- Registration Number
- JPRN-jRCT1030200279
- Lead Sponsor
- Tanosaki Ryuji
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Suspended
- Sex
- All
- Target Recruitment
- 100
(1) Blood type (ABO, Rh type) and irregular antibody are negative (Keio University Hospital)
(2) The following infectious disease screening antigen antibody test is negative or within the blood donation standard range: syphilis serological test, hepatitis B virus test (HBs antigen, HBs antibody, HBc antibody), hepatitis C virus test (HCV antibody) ), HIV test (HIV-1, 2 antibody), HTLV-1 antibody test, human parvovirus test, nucleic acid amplification test (HBV, HCV, HIV) (when antibody test of each virus becomes positive) (consigned to Nisseki And carry out)
(3) SARS-CoV-2 neutralizing antibody titer (conducted at National Institute of Infectious Diseases Toyama Government Building) is high titer positive (1: 160 or more is a guide).
(4) SARS-CoV-2 blood PCR (conducted at the National Institute of Infectious Diseases Murayama Government Building) is negative.
1) A clinically meaningful irregular antibody becomes positive,
2) The infectious disease screening is positive or out of the blood donation standard range.
3) SARS-CoV-2 neutralizing antibody titer was judged to be low (1:80 or less is a guideline. Since the criteria are not sufficiently standardized, it will be decided in consultation with the National Institute of Infectious Diseases)
4) SARS-CoV-2 PCR is positive
5) The person in charge of business determines that it is inappropriate
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Safety of COVID-19 CP donor
- Secondary Outcome Measures
Name Time Method Feasibility of COVID-19 CP Banking